Vismodegib

Vismodegib is an investigational drug for the treatment of various types of cancer. It has completed a Phase II clinical trial for metastasizing basal-cell carcinoma and is in Phase II trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma.

Mechanism of action
The substance acts as an antagonist of the smoothened receptor (SMO) which is part of the hedgehog signaling pathway. This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas.